))
Post-Partum Depression, Endometrial Cancer, mCRC, and Ebolavirus
Manage episode 407556912 series 3561458
Content provided by Emma Nichols, PhD and Emma Hitt Nichols. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Emma Nichols, PhD and Emma Hitt Nichols or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Check out our free downloads at nascentmc.com:
- Implementing AMA Style – 8 Things to Get Right in Your Next Project
- Needs Assessments – 7 Essentials for Getting Funded
- Working With Your Medical Writer – 8 Ways to Get the Most out of Them
See the full write ups for today's episodes at nascentmc.com/podcast
In this week's New FDA Approval's podcast episode, Dr. Emma Hitt Nichols discusses the latest FDA approvals from July 31, 2023 – August 4, 2023. Please check back every Monday morning so that you can stay up to date.
Here are the highlights:
· The FDA has approved Zurzuvae, the first oral medication for postpartum depression, showing significant improvement in patient symptoms compared to placebo groups.
· Jemperli, a PD-1 inhibitor, has been approved by the FDA for use with chemotherapy in adult patients with primary advanced or recurrent endometrial cancer with specific mutations. The drug is already approved for use as a single agent in similar cases and is now indicated for use in the first-line setting, with discussions for a broader indication underway with the FDA.
· The FDA has approved the oral drug Lonsurf, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer previously treated with specific chemotherapy and targetd therapies. Lonsurf, initially approved as a single agent in 2015, is also approved for advanced metastatic gastric or gastroesophageal junction adenocarcinoma.
· The FDA has approved an expanded indication for Ervebo, a vaccine now indicated for the prevention of disease caused by Zaire ebolavirus for individuals aged 12 months and older.
Did you know, you can access our nascentmc.com/podcast page and search the notes from this podcast! So for example, if you search a term like "diabetes" it will bring up all the diabetes related therapeutic agents approved since the first episode on May 15 of this year. We're also including the prescribing information with each summary too. Check it out at nascentmc.com/podcast.
Intro and outro music
54 episodes
Share
